GlaxoSmithKline News and Research

RSS

Identification of third microRNA target triggers milestone payment from GSK to Regulus

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has identified a third microRNA target in its alliance with GlaxoSmithKline (GSK), triggering a preclinical milestone payment from GSK.

21 Jul 2011

SuperGen closes acquisition of Astex

SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced it has closed the transaction to acquire Astex Therapeutics Limited, a privately held, UK-based biotechnology company developing targeted therapies.

21 Jul 2011

U.S. FDA approves 2011-2012 influenza vaccine formulation

The U.S. Food and Drug Administration announced today that it has approved the influenza vaccine formulation for the 2011-2012 vaccine that will be used by the six manufacturers licensed to produce and distribute influenza vaccine for the United States.

19 Jul 2011

Flu vaccine for 2011-12 season approved and ready

According to an announcement from the Food and Drug Administration (FDA) on Monday, it has approved the new flu vaccine for the season beginning this year. Each year the FDA works with other federal agencies and global health experts to design a vaccine to protect against the three viral strains most likely to cause the flu.

19 Jul 2011

EC grants marketing authorization for BENLYSTA to treat SLE

GlaxoSmithKline and Human Genome Sciences, Inc. announced today that the European Commission has granted marketing authorization for BENLYSTA 10mg/kg as an add-on therapy in adult patients with active autoantibody-positive systemic lupus erythematosus, with a high degree of disease activity, despite standard therapy.

14 Jul 2011

Gilead becomes first company to license drugs to Medicines Patent Pool

"In the first agreement between a pharmaceutical company and the new international Medicines Patent Pool, Gilead Sciences announced Tuesday that it would license four of its AIDS and hepatitis B drugs to the pool," the New York Times reports.

13 Jul 2011

GlaxoSmithKline's Boostrix receives FDA approval to prevent tetanus, diphtheria, and pertussis

The U.S. Food and Drug Administration today approved Boostrix vaccine to prevent tetanus, diphtheria, and pertussis (whooping cough) in people ages 65 and older.

11 Jul 2011

FDA approves BOOSTRIX to prevent tetanus, diphtheria and pertussis in older people

The U.S. Food and Drug Administration (FDA) has approved BOOSTRIX for use in adults 65 years of age and older for active booster immunization against tetanus, diphtheria and pertussis.

11 Jul 2011

EU countries should pool funding to create 'prize' for bringing new antibiotics to market, report says

"European policy makers were urged Wednesday to find viable financial incentives to get drug companies to discover new antibiotics, because the lack of fresh supplies poses acute dangers to health care and efforts against infectious diseases," according to a report by the Office of Health Economics and funded by GlaxoSmithKline, Dow Jones/Wall Street Journal reports.

8 Jul 2011

HIV drug linked to accelerated and early aging

New research published this Sunday reveals that a class of generic AIDS drugs often used to treat HIV in Africa and other poor regions can cause premature aging and lead to age-related illnesses such as heart disease and dementia.

27 Jun 2011

Some drug mixtures may be fatal for elderly: study

British scientists warn that well known brands of hay fever tablets, painkillers and sleeping pills pose a previously unknown threat to elderly people’s health when taken together. Many are available over the counter at pharmacies as well as being prescribed by GPs, nurses and chemists they said.

23 Jun 2011

Results of African malaria vaccine trial expected later this year

The final phase of testing for GlaxoSmithKline Biologicals' malaria vaccine, RTS,S, is underway in seven sub-Saharan African countries, and "if the results, due to be released later this, year confirm the vaccine's efficacy in preventing malaria, it could be made available as early as 2015," IRIN reports.

22 Jun 2011

Concert earns $4M milestone payment from GSK collaboration

Concert Pharmaceuticals, Inc. today announced that it has achieved a milestone in its strategic alliance with GlaxoSmithKline for its HIV protease inhibitor development program, resulting in a $4 million milestone payment to Concert.

20 Jun 2011

Pharma IQ publishes results of Industry-wide distribution survey

Pharma IQ has just published the results of an Industry-wide Pharmaceutical Distribution Survey, conducted recently among 3,000 pharmaceutical distribution specialist with over 83 % of those surveyed directly responsible for distribution at their respective companies.

20 Jun 2011

Menafrivac more effective, less expensive than older meningitis vaccines, studies say

The meningococcal vaccine MenAfriVac, which is made by the Indian generic drug company Serum Institute, is "dramatically better" at producing a protective effect among African children in three countries than "older so-called meningococcal polysaccaride vaccines, including Mencevax from GlaxoSmithKline," according to a paper describing two studies published in the New England Journal of Medicine, Reuters reports.

17 Jun 2011

Pharma IQ launches Global HTA and CER Forum

Pharma IQ is pioneering new HTA discussion platform with launch of the first ever HTA Online event - Global HTA and CER Forum, which will take an innovative form of 12 online session over the course of August.

15 Jun 2011

Large donations help GAVI raise $4.3B, exceeding goal

"Large donations from the U.K., Norway and the Bill & Melinda Gates Foundation helped a global vaccine charity raise $4.3 billion at a summit Monday, exceeding its targets and allowing it to carry out all its immunization plans through 2015," the Wall Street Journal reports.

15 Jun 2011

Billions committed for children’s vaccines

British Prime Minister David Cameron has pledged £814m to help vaccinate children around the world against preventable diseases like pneumonia. He made the announcement at a summit in London where countries are being asked to give an extra £2.3bn ($3.7bn) by 2015 for child vaccines. He said, “Three children die every minute from pneumonia alone. Waiting is not the right thing to do and I don't think that 0.7 per cent of our gross national income is too high a price to pay for saving lives.”

13 Jun 2011

FDA approves Valeant's Potiga Tablets for treatment of partial-onset seizures

Valeant Pharmaceuticals International, Inc. and GlaxoSmithKline announced today that the U.S. Food and Drug Administration (FDA) has approved Potiga Tablets, a potassium channel opener, as adjunctive treatment of partial-onset seizures in patients aged 18 years and older.

13 Jun 2011